180 related articles for article (PubMed ID: 32329160)
1. Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.
van der Aart-van der Beek AB; van Raalte DH; Guja C; Hoogenberg K; Suchower LJ; Hardy E; Sjöström CD; Heerspink HJL
Diabetes Obes Metab; 2020 Sep; 22(9):1556-1566. PubMed ID: 32329160
[TBL] [Abstract][Full Text] [Related]
2. Effect of once-weekly exenatide on estimated glomerular filtration rate slope depends on baseline renal risk: A post hoc analysis of the EXSCEL trial.
van der Aart-van der Beek AB; Clegg LE; Penland RC; Boulton DW; Sjöström CD; Mentz RJ; Holman RR; Heerspink HJL
Diabetes Obes Metab; 2020 Dec; 22(12):2493-2498. PubMed ID: 32803900
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
Grimm M; Han J; Weaver C; Griffin P; Schulteis CT; Dong H; Malloy J
Postgrad Med; 2013 May; 125(3):47-57. PubMed ID: 23748506
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.
Malloy J; Meloni A; Han J
Postgrad Med; 2013 May; 125(3):58-67. PubMed ID: 23748507
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.
Guja C; Frías JP; Suchower L; Hardy E; Marr G; Sjöström CD; Jabbour SA
Diabetes Ther; 2020 Jul; 11(7):1467-1480. PubMed ID: 32306296
[TBL] [Abstract][Full Text] [Related]
6. Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial.
Muskiet MHA; Bunck MC; Heine RJ; Cornér A; Yki-Järvinen H; Eliasson B; Joles JA; Diamant M; Tonneijck L; van Raalte DH
Diabetes Res Clin Pract; 2019 Jul; 153():14-22. PubMed ID: 31078666
[TBL] [Abstract][Full Text] [Related]
7. Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
Clegg LE; Penland RC; Bachina S; Boulton DW; Thuresson M; Heerspink HJL; Gustavson S; Sjöström CD; Ruggles JA; Hernandez AF; Buse JB; Mentz RJ; Holman RR
Cardiovasc Diabetol; 2019 Oct; 18(1):138. PubMed ID: 31640705
[TBL] [Abstract][Full Text] [Related]
8. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
[TBL] [Abstract][Full Text] [Related]
9. Albuminuria-lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes: A randomized and placebo-controlled study.
Sivalingam S; Wasehuus VS; Rotbain Curovic V; Blond MB; Hansen TW; Persson F; Rossing P
Diabetes Obes Metab; 2024 Jan; 26(1):54-64. PubMed ID: 37722966
[TBL] [Abstract][Full Text] [Related]
10. Albuminuria-lowering effect of dapagliflozin, exenatide, and their combination in patients with type 2 diabetes: A randomized cross-over clinical study.
van der Aart-van der Beek AB; Apperloo E; Jongs N; Rouw DB; Sjöström CD; Friedli I; Johansson L; van Raalte DH; Hoogenberg K; Heerspink HJL
Diabetes Obes Metab; 2023 Jun; 25(6):1758-1768. PubMed ID: 36843215
[TBL] [Abstract][Full Text] [Related]
11. Exenatide once weekly versus daily basal insulin as add-on treatment to metformin with or without a sulfonylurea: a retrospective pooled analysis in patients with poor glycemic control.
Grimm M; Li Y; Brunell SC; Blase E
Postgrad Med; 2013 Sep; 125(5):101-8. PubMed ID: 24113668
[TBL] [Abstract][Full Text] [Related]
12. Exenatide once weekly for the treatment of type 2 diabetes mellitus: clinical results in subgroups of patients using different concomitant medications.
Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
Postgrad Med; 2012 Jul; 124(4):33-40. PubMed ID: 22913892
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and tolerability of therapy with exenatide once weekly vs basal insulin among injectable-drug-naïve elderly or renal impaired patients with type 2 diabetes in the United States.
Loughlin AM; Qiao Q; Nunes AP; Öhman P; Ezzy S; Yochum L; Clifford CR; Gately R; Dore DD; Seeger JD
Diabetes Obes Metab; 2018 Apr; 20(4):898-909. PubMed ID: 29193561
[TBL] [Abstract][Full Text] [Related]
14. Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials.
Mann JFE; Hansen T; Idorn T; Leiter LA; Marso SP; Rossing P; Seufert J; Tadayon S; Vilsbøll T
Lancet Diabetes Endocrinol; 2020 Nov; 8(11):880-893. PubMed ID: 32971040
[TBL] [Abstract][Full Text] [Related]
15. Hormone-substrate changes with exenatide plus dapagliflozin versus each drug alone: The randomized, active-controlled DURATION-8 study.
Ferrannini E; Baldi S; Frías JP; Guja C; Hardy E; Repetto E; Jabbour SA; DeFronzo RA
Diabetes Obes Metab; 2020 Jan; 22(1):99-106. PubMed ID: 31469220
[TBL] [Abstract][Full Text] [Related]
16. Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
Fudim M; White J; Pagidipati NJ; Lokhnygina Y; Wainstein J; Murin J; Iqbal N; Öhman P; Lopes RD; Reicher B; Holman RR; Hernandez AF; Mentz RJ
Circulation; 2019 Nov; 140(20):1613-1622. PubMed ID: 31542942
[TBL] [Abstract][Full Text] [Related]
17. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.
van Ruiten CC; van der Aart-van der Beek AB; IJzerman RG; Nieuwdorp M; Hoogenberg K; van Raalte DH; Heerspink HJL
Diabetes Obes Metab; 2021 Aug; 23(8):1851-1858. PubMed ID: 33908691
[TBL] [Abstract][Full Text] [Related]
18. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular outcomes associated with a new once-weekly GLP-1 receptor agonist vs. traditional therapies for type 2 diabetes: a simulation analysis.
Peskin BR; Shcheprov AV; Boye KS; Bruce S; Maggs DG; Gaebler JA
Diabetes Obes Metab; 2011 Oct; 13(10):921-7. PubMed ID: 21624032
[TBL] [Abstract][Full Text] [Related]
20. Dynamic risk factors associated with non-severe hypoglycemia in patients treated with insulin glargine or exenatide once weekly.
Paul SK; Maggs D; Klein K; Best JH
J Diabetes; 2015 Jan; 7(1):60-7. PubMed ID: 25168883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
